Protected: FDA’s Five Peptide Warning Letters: Four Takeaways for RUO Sellers
There is no excerpt because this is a protected post.
Three States, One Message: What Mississippi and South Carolina Just Said About Research-Grade Peptides
And why the standard of care is the real issue in all fifty states, not three By Dustin Robinson, Esq., CPA | LumaLex Law | Peptides · Telehealth · Regulatory Compliance In mid-August 2026, within roughly a day of each other, two states published nearly identical notices about the same product category. The Mississippi […]
Vermont Joins a Fast-Moving Trend: What the State-by-State Crackdown on Private Equity in Health Care Means for MSOs and Telehealth
Vermont’s new clinical decision-making law isn’t an isolated event. It’s the latest entry in a wave of state legislation — from California and Oregon to Massachusetts, Connecticut, Maine, Pennsylvania, and North Carolina — that has reshaped the compliance landscape for MSO/PC arrangements, telehealth platforms, and their private equity sponsors since 2025. Understanding Vermont on its […]
The License Holder and the Operator: What Healthcare, Cannabis, and Fintech All Have in Common
By Dustin Robinson, CPA, Founding & Managing Attorney, LumaLex Law There is a structure that shows up over and over again in the industries we work in, and most people never notice that it is essentially the same structure. A telehealth company cannot own the medical practice, so it forms a management services organization that […]
California Draws a Line Around the “Friendly PC”: What MSO-Backed Healthcare Platforms Need to Know
For years, the friendly professional corporation model has been one of the core structures behind investment in medicine. The basic idea is familiar: a physician owns the professional corporation that employs clinicians and holds the medical licenses. A management services organization, or MSO, sits beside the PC and handles the non-clinical side of the business: […]
Hedging Into Telehealth: What RUO Peptide Companies Need to Know Before Building a Medical Channel
The signal from the top has been consistent: current HHS leadership wants peptide access to move through lawful medical channels, and it has been openly skeptical of the research-use-only market that grew while those channels were closed. The Pharmacy Compounding Advisory Committee meeting on July 23rd and 24th was the first formal step in that […]
The July 2026 PCAC Peptide Meeting
On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee, known as PCAC, met at the agency’s White Oak campus in Silver Spring, Maryland to consider whether seven peptides should be added to the Section 503A Bulk Drug Substances List. For anyone operating in the peptide, telehealth, or compounding space, this was one […]
Why High-Income Regulated Businesses Get Audited and How to Prepare
Fast growth is exciting, especially in emerging industries where revenue can scale quickly. But for RUO peptide companies, telehealth companies, cannabis operators, psychedelic ventures, kratom brands, and crypto businesses, high revenue can also bring a different kind of attention. Seven- and eight-figure years are no longer unusual in these spaces. That kind of income can […]
How to Start a Peptide Company: A Practical Guide for RUO Founders
The RUO peptide space has grown quickly over the past few years, and with that growth has come a new wave of founders trying to figure out how to build the business the right way from the beginning. For many operators, the focus starts with the product: what to sell, where to source it, how […]
FDA Warning Letters for GLP-1 Telehealth and Peptide Companies: What Your Website Needs to Fix
The FDA has sent an escalating number of warning letters to telehealth companies offering compounded GLP-1 medications and peptides since September 2025. The letters share a common theme: the FDA is looking closely at website language and using those claims as evidence of misbranding and unapproved new drug violations under the Federal Food, Drug, and […]
